Xenakis1: Drug study: Haloperidol antipsychotic effects on behavioral phenotypes in 73 F1 hybrids of Collaborative Cross strains of mice (RIX) (2020)

Giusti-Rodríguez P, Xenakis JG, Crowley JJ, Nonneman RJ, DeCristo DM, Ryan A, Quackenbush CR, Miller DR, Shaw GD, Zhabotynsky V, Sullivan PF, Manuel de Villena FP, Zou F. Antipsychotic Behavioral Phenotypes in the Mouse Collaborative Cross Recombinant Inbred Inter-Crosses (RIX). G3 (Bethesda). 2020 Sep 2;10(9):3165-3177. doi: 10.1534/g3.120.400975.   PubMed 32694196     FullText


         
A battery of behavioral tests were performed in 73 RIX lines treated with haloperidol or placebo in order to monitor the development of antipsychotic-induced adverse drug reactions.

Note on studied population: Six mice were removed from the study due to technical difficulties in phenotyping.

Experimental groups in this study:
• Haloperidol treatment group     • Placebo treatment group    

Procedures conducted:
• body weight 
• inclined screen test  Latency to move all four paws.
• open field test  Locomotor activity, anxiety, stereotypy.
• behavior observation  Vacuous chewing, tongue protrusion, jaw tremor.
• drug and metabolite quantification  Plasma haloperidol concentration.

Xenakis1 downloads
• Download Xenakis1 project data set     animal data, as uploaded
• Download Xenakis1 animal data matrix     with factor-related expansion applied as necessary
• Download Xenakis1 strain means, SD, N, etc.     one row per strain/sex/measure
Investigators James G Xenakis       University of North Carolina,  Chapel Hill, NC
Paola Giusti-Rodriguez       University of North Carolina,  Chapel Hill, NC
Patrick F Sullivan       University of North Carolina,  Chapel Hill, NC
Fernando Pardo-Manuel de Villena       University of North Carolina,  Chapel Hill, NC
Fei Zou       University of North Carolina,  Chapel Hill, NC
Participants Crowley JJ, Nonneman RJ, DeCristo DM, Ryan A, Quackenbush CR, Miller DR, Shaw GD, Zhabotynsky V
ContactFei Zou     fzou@bios.unc.edu
Funding Provided ByNIH MH090338, HG006582; University Cancer Research Funds granted to the Lineberger Comprehensive Cancer Center (MCR012CCRI)
Project type Phenotype strain survey data set
MPD identifiersXenakis1     MPD:1006
Data changelog No updates/corrections.       Initial release date: 09/2019.
Formatted citation
Click above to copy-paste the entire citation for this MPD web page.
Mice: CC RIX   73 strains   ♀♂   age 7-13wks   2 experimental groups

Select table page: First Prev 1 - 10 / 17 (17) Next Last
Sort/
Pick
Data set
Procedure / Protocol
Treatment
Phenotype Measure / Variable (click to view)
Panel
No. of Strains
Sex
Age
Sample Size (Avg)
    Xenakis1 body weight (none) body weight, placebo group   [g]  bw_cont   111150     pre-treatment    post-treatment CC RIX 73 both 7-13wks N=3
    Xenakis1 body weight haloperidol body weight, treatment group   [g]  bw_Rx   111152     pre-treatment    post-treatment CC RIX 73 both 7-13wks N=3
    Xenakis1 inclined screen test (none) latency to move all four paws (extrapyramidal symptoms), placebo group   [s]  latency_cont   111154     pre-treatment    post-treatment CC RIX 73 both 7-9wks N=3
    Xenakis1 inclined screen test haloperidol latency to move all four paws (extrapyramidal symptoms), treatment group   [s]  latency_Rx   111156     pre-treatment    post-treatment CC RIX 73 both 7-9wks N=3
    Xenakis1 open field test (none) distance traveled, 30 min test, placebo group   [cm]  distance_cont   111158     pre-treatment    post-treatment CC RIX 73 both 7-13wks N=3
    Xenakis1 open field test haloperidol distance traveled, 30 min test, treatment group   [cm]  distance_Rx   111160     pre-treatment    post-treatment CC RIX 73 both 7-13wks N=3
    Xenakis1 open field test (none) vertical activity (beam breaks), 30 min test, placebo group   [n]  vertical_cont   111162     pre-treatment    post-treatment CC RIX 73 both 7-13wks N=3
    Xenakis1 open field test haloperidol vertical activity (beam breaks), 30 min test, treatment group   [n]  vertical_Rx   111164     pre-treatment    post-treatment CC RIX 73 both 7-13wks N=3
    Xenakis1 open field test (none) time spent in center of arena, 30 min test, placebo group   [s]  center_cont   111166     pre-treatment    post-treatment CC RIX 73 both 7-13wks N=3
    Xenakis1 open field test haloperidol time spent in center of arena, 30 min test, treatment group   [s]  center_Rx   111168     pre-treatment    post-treatment CC RIX 73 both 7-13wks N=3
    All boxes             To see more rows use the paging control at top.


  •   Or, add these measures to your collection.
       
  •     no folder
  •     put them in new folder